As previously reported, Wedbush initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $35 price target The firm notes its lead candidate obexelimab is a CD19 mAb that ...

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Immunome (IMNM – Research Report), with a price target of $33.00. The company’s shares closed yesterday ...

Andrew Harnik via Getty Images Long-time Tesla bull Dan Ives, an analyst at Wedbush Securities, says Elon Musk is the only one who can turn the EV maker's reputation around and the billionaire ...

Wedbush analysts called Palantir one of their "top names" to own in 2025 despite recent losses. Shares of Palantir have lost one-third of their value in the wake of a report last month that the ...

However, Wedbush said its recent checks with customers and partners indicate an acceleration in deal flow this quarter, reinforcing confidence in Azure’s growth outlook. “AI revenue run rate ...

Delays in AI improvements and the next-generation Siriwhich are currently anticipated with iPhone 17have put pressure on Apple shares, claims Wedbush analyst Daniel Ives. A sluggish tech ...

Long-time Tesla bull Dan Ives, an analyst at Wedbush Securities, says Elon Musk is the only one who can turn the EV maker's reputation around and the billionaire needs to show he is balancing his ...

Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.51) per share for the quarter, up from their prior estimate of ($0.72). Wedbush has a “Outperform ...

Check Out Our Latest Stock Analysis on ARHS Arhaus Trading Down 5.8 % Shares of NASDAQ ARHS opened at $8.97 on Monday. The company has a market cap of $1.26 billion, a price-to-earnings ratio of ...

Wedbush maintained its Outperform rating on Apple (NASDAQ:AAPL) noting that the company's next stage of product and AI driven services growth is still ahead. The firm has a $325 price target on ...

Shares of Zenas BioPharma (NASDAQ:ZBIO) rose on Thursday after Wedbush launched the newly IPO’ed biotech's coverage with an Outperform recommendation, citing its lead asset obexelimab’s safety ...

Investing.com -- The negative investor sentiment around Microsoft (NASDAQ:MSFT) stock is “way overdone” and 2025 is expected to be an inflection point of growth for the tech giant, according to ...